Key Takeaways
- • BC Partners acquires approximately 50% co-controlling stake in InfoRLife, a Swiss pharmaceutical CDMO specializing in ready-to-use intravenous infusion bags, valuing the company at approximately $1.5 billion.
- • The transaction represents BC Partners Fund XII's second investment from its €5 billion flagship fundraising target, reinforcing the firm's strategic focus on pharmaceutical supply chain assets.
- • InfoRLife's founding shareholders, including CEO Sergio Dusci and the founding families of parent company ACS Dobfar, retain the remaining ownership interest post-completion, ensuring continued founder involvement in the business.
- • BC Partners plans to support InfoRLife's growth through centralized management structure optimization and commercial platform enhancement, capitalizing on rising healthcare demand for pre-prepared infusion products that improve patient safety and hospital efficiency.
- • InfoRLife operates manufacturing facilities across Switzerland, Romania, and Tunisia, positioning the company within a market benefiting from healthcare providers' increasing adoption of ready-to-use injectable medicines to reduce medication errors and operational costs.
Summary
BC Partners has agreed to acquire a co-controlling stake of approximately 50% in InfoRLife, a Swiss-based contract development and manufacturing organization (CDMO) focused on ready-to-use injectable medicines. The acquisition values InfoRLife at around $1.5 billion, according to Bloomberg. The transaction marks BC Partners' second investment from its latest flagship fund, BC Partners Fund XII, which is currently midway through its €5 billion fundraising target.
InfoRLife, founded in 2002 as a division of ACS Dobfar, manufactures ready-to-use injectable medicines supplied in intravenous infusion bags. The company operates manufacturing facilities in Switzerland, Romania, and Tunisia, serving hospitals and healthcare systems across multiple geographies. The business operates in a structurally favorable market segment characterized by healthcare providers' growing preference for pre-prepared infusion products, which enhance patient safety, reduce medication errors, and improve hospital operational efficiency.
Under the transaction terms, BC Partners will acquire its stake from InfoRLife CEO Sergio Dusci and the founding families behind ACS Dobfar, who will retain the remaining ownership interest in the company. This ownership structure ensures continued founder involvement post-completion while providing BC Partners with operational control alongside the existing shareholders.
BC Partners has positioned the investment as an opportunity to accelerate InfoRLife's development through enhanced corporate governance and commercial expansion. The firm plans to strengthen the business by establishing a more centralized management structure and enhancing the commercial platform—areas the private equity investor identified as value-creation levers. This transaction continues BC Partners' systematic strategy of building pharmaceutical supply chain positions, complementing prior healthcare investments in generic drug manufacturers Biogaran and Synthon.
The acquisition reflects BC Partners' conviction in the structural growth drivers within pharmaceutical manufacturing and hospital supply chain services, particularly within the specialty pharmaceuticals and injectable medicines segments where demand tailwinds support expansion.
InfoRLife, founded in 2002 as a division of ACS Dobfar, manufactures ready-to-use injectable medicines supplied in intravenous infusion bags. The company operates manufacturing facilities in Switzerland, Romania, and Tunisia, serving hospitals and healthcare systems across multiple geographies. The business operates in a structurally favorable market segment characterized by healthcare providers' growing preference for pre-prepared infusion products, which enhance patient safety, reduce medication errors, and improve hospital operational efficiency.
Under the transaction terms, BC Partners will acquire its stake from InfoRLife CEO Sergio Dusci and the founding families behind ACS Dobfar, who will retain the remaining ownership interest in the company. This ownership structure ensures continued founder involvement post-completion while providing BC Partners with operational control alongside the existing shareholders.
BC Partners has positioned the investment as an opportunity to accelerate InfoRLife's development through enhanced corporate governance and commercial expansion. The firm plans to strengthen the business by establishing a more centralized management structure and enhancing the commercial platform—areas the private equity investor identified as value-creation levers. This transaction continues BC Partners' systematic strategy of building pharmaceutical supply chain positions, complementing prior healthcare investments in generic drug manufacturers Biogaran and Synthon.
The acquisition reflects BC Partners' conviction in the structural growth drivers within pharmaceutical manufacturing and hospital supply chain services, particularly within the specialty pharmaceuticals and injectable medicines segments where demand tailwinds support expansion.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.